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Enhancement of ketoconazole dissolution rate 
by the liquisolid technique
The study was conducted to enhance the dissolution rate of 
ketoconazole (KCZ) (a poorly water-soluble drug) using the 
liquisolid technique. Microcrystalline cellulose, colloidal 
silica, PEG400 and polyvinyl pyrrolidone (PVP) were em-
ployed as a carrier, coating substance, nonvolatile solvent 
and additive in the KCZ liquisolid compact formulation, 
respectively. The drug-to-PEG400 and carrier-to-coating 
ratio variations, PVP concentration and aging effects on the 
in vitro release behavior were assessed. Differential scan-
ning calorimetry (DSC) and X-ray powder diffraction 
(XRD) data revealed no alterations in the crystalline form 
of the drug and the KCZ-excipient interactions within the 
process. The load factor and the drug release rate were sig-
nificantly enhanced compared to directly compressed tab-
lets in the presence of the additive. Increasing the PEG400-
to-drug ratio in liquid medications enhanced the 
dissolution rate remarkably. The dissolution profile and 
hardness of liquisolid compacts were not significantly al-
tered by keeping the tablets at 40 °C and relative humidity 
of 75 % for 6 months. With the proposed modification of the 
liquisolid process, it is possible to obtain flowable, com-
pactible liquisolid powders of high-dose poorly-water soluble 
drugs with an enhanced dissolution rate.
Keywords: ketoconazole, liquisolid, dissolution rate, Avicel, 
polymorphic changes
Dissolution of active elements of a solid dosage form with low aqueous solubility is 
an important issue that should be achieved before its absorption via the gastrointestinal 
(GI) tract (1). For pharmaceutical scientists, the low dissolution features of water-insoluble 
drugs are a major challenge (2, 3). The dissolution rate of a drug with low aqueous solubil-
ity at its absorption site is the main controlling parameter that affects the absorption rate 
of the drug prepared as an orally delivered solid dosage form, i.e. release rate is the rate-
verifying step in drug absorption (4). There are numerous techniques for enhancing the 
dissolution rate of these drugs, including (a) size reduction to increase the surface area (3, 
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use of pro-drug and drug derivatives such as strong electrolyte salt forms that generally 
have a superior dissolution rate (8); and (e) manipulation of the solid state of drugs in order 
to obtain better drug dissolution by reducing the crystallinity of drug material through 
construction of solid solutions (9). The most common method is micronization to increase 
the drug surface area but, in practice, the outcome of micronization is usually unsatisfac-
tory, particularly when the drugs are formulated as capsules or tablets (10). As a conse-
quence of hydrophobicity, micronized drugs have a tendency to agglomerate; hence, their 
available surface area will decrease. Several studies have shown that the most reliable 
technique is the liquisolid method for enhancing the release rate of drugs with poor solu-
bility in aqueous media, which has been effectively used for such drugs (11‒13). However, 
preparing high doses of drugs into liquisolid compacts is one of the limitations of this 
method. In this case, in order to obtain satisfactory flowability and compatibility of liqu-
isolid powders, the carrier and coating substances should be added at high levels to in-
crease the weight of each tablet and make it difficult to swallow (2, 3, 14‒16). As reported 
in our previous study, by adding some compounds like polyvinyl pyrrolidone (PVP) to 
liquid medications (microsystems), it is possible to manufacture suitable liquisolid tablets 
containing high drug concentrations. By doing so, a lower quantity of carrier is needed to 
obtain dry powders with free flowability and acceptable compatibility, as shown by carba-
mazepine liquisolid tablets with a remarkably increased dissolution rate (14). The reasons 
for dissolution rate enhancement of liquisolid formulations in the presence of PVP are 
mainly attributed to inhibition of crystal growth (i.e., PVP inhibits drug precipitation from 
a supersaturated liquid medication) as well as to the increase of the exposed drug surface 
area in the dissolution medium due to adsorption on the carrier (14).
Ketoconazole (KCZ) is one of the poorly soluble drugs with high permeability in GI 
(class II) and its release rate in the GI tract controls its oral absorption rate (17, 18). Conse-
quently, in addition to permeability, the dissolution rate and solubility of the drug are 
crucial for its oral bioavailability (19‒21). GI injuries may also increase due to this unfavor-
able characteristic that increases the duration of the drug’s contact with the GI mucosa; 
therefore, enhancement of the dissolution rate of poorly soluble drugs by liquisolid com-
pacts appears to be a good choice. Some methods have been used to speed up the dissolu-
tion of KCZ, including the use of solid dispersions (22, 23) and the formation of soluble 
complexes with additives such as cyclodextrin (24, 25), with varying degrees of success.
In this study, the capability of the liquisolid technique was examined by preparing 
liquisolid systems of KCZ in order to increase its dissolution rate as a water-insoluble drug. 
To this end, KCZ was formulated in liquisolid tablets with various drug-to-solvent ratios 
at the same concentrations of powder excipients and PVP in their liquid medications. The 
in vitro drug release study of liquisolid systems was conducted by comparing the dissolu-
tion behavior of directly compressed tablets (DC) using a USP apparatus II-paddle stirrer 
in SGF dissolution media (pH = 1.2).
EXPERIMENTAL
Materials
Ketoconazole was provided by Sobhan Co. (Rasht, Iran). Cellulose with a coarse gran-
ular microcrystalline structure (Avicel PH101), amorphous silicon dioxide (silica) in nano-
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meter size and sodium starch glycolate were supplied by Mingtai Chemical (Taiwan) and 
Yung Zip Chemical (Taiwan), respectively. Polysorbate 80 (Tween 80), propylene glycol 
(PG), polyethylene glycol 400 (PEG), PEG 200, glycerin, industrial grade corn starch, mono-
hydrate lactose, sorbitol and sodium chloride were purchased from Merck (Germany). 
Polyvinyl pyrrolidone K25 (PVP) was obtained from BASF (Germany) and hydroxypropyl 
methylcellulose K4M (HPMC) was purchased from Colorcon (England). All the other 
chemical substances were of analytical grade.
Preparation of conventional and liquisolid tablets
KCZ regular tablets (directly compressed tablets (DC) or physical mixture (PM)) were 
formulated by blending KCZ with microcrystalline cellulose and silica. The blend was 
agitated for 10 min with sodium starch glycolate (SSG) (as a disintegrating agent). Then, a 
die with a 10-mm punch was used to compress the blend using a manual tableting ma-
chine (Riken, Japan) and applying adequate compression load to fabricate compacts of 7‒8 
SC hardness (Strong Cobb). Each tablet contained 100 mg of KCZ, 400 mg of cellulose (as 
a carrier), 20 mg of silica in nanometer range (as a coating substance) and 25 mg of SSG.
Different liquisolid compacts (Table I) were also prepared. KCZ was dispersed in 
PEG 400 (liquid medication was prepared using PEG 400 as solvent). PVP was then dis-
solved in PEG 400 containing ketoconazole. After that, a binary blend of the carrier and 
coating substances was added to the resultant liquid medication under continuous agita-
tion in a mortar and finally mixed with 5 % (m/m) of SSG as disintegrant. The final mix-
ture was compacted using the manual tableting machine to obtain a compact hardness of 
7‒8 SC. Key formulation features of the prepared KCZ liquisolid formulations are given 
in Table I.
Drug content evaluation test
Ten tablets were weighed and ground into a fine powder. The amount of powder 
equivalent to 200 mg of KCZ was weighed accurately into a 100 mL calibrated flask, 70 mL 
Table I. Key formulation characteristics of the prepared ketoconazole liquisolid compacts
F3F2F1









Weight of each compacted 
liquisolid tablet (g)
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of ethanol was added, and the flask was shaken for about 12 h. Then, the volume was made 
up and filtered using Whatmann No 42 filter paper. The filtrate was diluted appropriately 
and analyzed by spectrophotometry.
Solubility studies
PEG 200, PEG 400, glycerin, polysorbate 80 and PG, as five different nonvolatile sol-
vents, were employed and their solubility was studied to determine the proper dissolution 
or suspension of the nonvolatile solvent of KCZ in liquid medications. In this regard, satu-
rated drug-solvent solutions were made by putting an excess drug into the vessel and agi-
tating it on a shaker (Velp, Italy) under constant vibration at 25 °C for 48 h. The solutions 
were filtered through a Millipore filter with a pore diameter of 0.45 μm, then diluted and 
evaluated at a wavelength of 284.4 nm with a UV spectrophotometer (Shimadzu, Kyoto, 
Japan). The solubility of KCZ was obtained from the mean values of three measurements 
for each sample (Table III).
Load factor calculation
To calculate the load factor (Lf), several concentrations (m/m) of polymer (PVP) were 
dissolved in PEG 400 (KCZ exhibited maximum solubility in PEG 400) (Table III). The 
system (liquid medication without KCZ) was incorporated into 30 g of the Avicel-silica 
powder blend as a carrier substance and mixed for 10 min. Flowability of 100 cm3 of liqu-
isolid systems was measured using a flowmeter (Erweka, Germany). The flow rate above 
10 cm3/s was considered a suitable flow rate for tableting in this study. Load factor amounts 
were calculated using the formula Lf = W/Q, where W and Q show the liquid medication 
and carrier material concentrations, respectively. The resultant Lf was used to obtain the 
amount of coating and carrier substances in each formulation. The Lf obtained in this 
study was 0.44.
 Spectrophotometric analysis
UV/visible spectrophotometry (Shimadzu-120, Kyoto, Japan) was used for the analysis 
of all the KCZ samples at 223.4 nm. Serially diluted aqueous stock solutions of the drug in 
simulated gastric fluids (SGF), pH = 1.2, were used to assemble standard curves and attain 
Table ІІ. Results of the spectrophotometric analysis of ketoconazole







M.-A. Molaei et al.: Enhancement of ketoconazole dissolution rate by the liquisolid technique, Acta Pharm. 68 (2018) 325–336.
 
concentrations in the range of 1.5‒50 μg mL–1. Data of each curve were acquired using the 
mean values of three measurements. Results of the spectrophotometric analysis are sum-
marized in Table ІІ.
Powder X-ray diffraction analysis
X-ray measurements of ground powders of the pure drug, PM/DC, liquisolid formula-
tions and excipients were made with the aid of X-ray diffraction (Siemens, Model D5000 
X-ray Diffractometer, Germany) on a quartz plate (with a low background) with a step size 
of 0.02°, at a scanning rate of 0.6°/min, using Cu Kα radiation (k = 1.5405 A°) from 5 to 70° 
working at 40 kV and 30 mA.
Differential scanning calorimetry (DSC)
A differential scanning calorimeter (DSC 60, Shimadzu, Japan) was used to examine 
the thermal attitude and thermograms of the samples. To this aim, the test samples were 
meticulously weighed (5 mg), then placed in sealed aluminum pans and a Shimadzu 
crimper was used to crimp the lids. A scanning rate of 20 °C per minute was used to 
evaluate the thermal attitude of the samples in the range of 30‒200 °C. Indium powder was 
employed as the standard.
In vitro drug release
A USP apparatus II-paddle stirrer (Erweka, DPT6R, Germany) was used to study release 
profiles of the pure drug, PM/DC and the liquisolid compressed tablets. The samples, all 
containing 100 mg of ketoconazole, were placed in a vessels containing 900 mL of simu-
lated gastric fluid (pH = 1.2) under rotational agitation of 100 ± 2 rpm at 37 ± 0.1 °C. At 
specified intervals (5, 10, 15, 20, 30, 45, 60 and 90 min), 5 mL of the prepared solutions was 
taken and filtered through a Millipore membrane with a pore diameter of 0.45 μm. After 
that, an equal amount of fresh dissolution fluid was added to the solution so as to retain a 
constant volume. To evaluate and record the cumulative drug release plot, UV spectropho-
tometry (Shimadzu, Kyoto, Japan) was conducted at a wavelength of 284.4 nm. In each of 
the diagrams, data were attained from the mean values of three measurements.
Optimized formulation stability analysis
Optimized liquisolid compressed tablets were kept for six months at 40 °C under 
relative humidity of 75 % in a sealed aluminum package to analyze the stability of the drug 
and liquisolid formulation according to the ICH standards. Drug hardness, content and its 
dissolution behavior were evaluated at specific intervals.
Statistical analysis
One-way ANOVA and Tukey’s multiple comparison tests were used for comparison 
of data between the samples. Statistical significance was set at p < 0.05. All the data were 
reported as mean ± standard deviations attained from three experimented samples.
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RESULTS AND DISCUSSION
Evaluation of the solid state properties of samples (XRD analysis) 
Drug precipitation might occur after its solution is adsorbed to the adsorbent. In other 
words, precipitation possibility depends on the drug dissolution and saturation degree 
into the solvent and solution or components’ interaction. It has been demonstrated that the 
dissolution behavior and bioavailability of the drug are crucial aspects that may be influ-
enced because of polymorphic changes (26). Therefore, the study of KCZ polymorphic 
changes in liquisolid formulations is important. Fig. 1 illustrates the XRD patterns of the 
pure drug, pure excipients, PM/DC (ketoconazole, cellulose, PVP, silica and SSG) and the 
liquisolid formulation. Distinct diffraction peaks at 2θ angles of 15.36, 19.56, 25, 27.47 and 
14, 22, 34 are the characteristic peaks of KCZ and cellulose (Avicel), respectively, which 
reflect their crystalline nature (27, 28). The PVP, silica and starch did not show any distinc-
tive peaks in XRD patterns, illustrating their amorphous nature. The pattern of the PM/DC 
and liquisolid systems had distinct diffraction peaks of the drug and one of cellulose 
peaks; however, intensity reduction of the peaks might be due to the dilution effect of the 
polymer and solubilization of the drug in liquisolid formulations.
In vitro drug solubility studies
Solubility of KCZ in various nonvolatile solvents (PG, PEG 400, PEG 200, glycerin, SGF 
and Tween 80) was evaluated to determine the drug solubility patterns in different media 
(Table IІI).
As indicated in Table III, the solubility order was PEG 400 > PEG 200 > PG > glycerin 
> Tween 80 > SGF, revealing that PEG 400 had the highest solubility (42.21 ± 2.07 mg mL–1) 
of the drug, with its large fraction being in molecular state. The drug dissolution rate can 
be directly related to its molar fraction in the liquid medication; therefore, PEG 400 was 
Fig. 1. X-ray diffraction patterns of pure ketoconazole, starch, PVP, Avicel, silica, physical mixture and 
liquisolid formulation.
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selected as the best nonvolatile solvent and used in liquisolid formulations. In fact, based 
on the Noyes and Whitney equation, the drug dissolution rate could be increased by in-
creasing the drug surface area; therefore, according to the results (Table III), PEG 400 con-
tains the largest fraction of the drug in the molecular form and this would enhance the 
drug dissolution rate due to the increased surface area (29). In addition, the load factor and 
dissolution efficiency data presented in Table I confirm these results; in other words, as 
mentioned in our previous study (14), addition of PVP as an additive to liquisolid micro-
systems (liquisolid formulations) enhances the load factor and improves the flowability 
and compatibility of liquisolid compressed tablets in comparison with DC tablets, result-
ing in an improvement of the dissolution rate. 
DSC evaluation
In order to recognize the physical properties of the samples and detect any probable 
interaction between the drug and excipients, the pure drug, excipients, PM/DC and liqu-
isolid formulation were subjected to DSC analysis (Fig. 2). The drug revealed a distinct 
Table IІI. Solubility of ketoconazole in various solvents
mg mL–1mmol mL–1








Fig. 2. DSC thermograms of pure ketoconazole, PVP, Avicel, silica, physical mixture and liquisolid 
formulation.
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endothermic peak at 148.6 ± 0.2 °C corresponding to its melting point; in addition, the PM 
and liquisolid formulation indicated a similar peak in this region. Therefore, based on the 
XRD and DSC results, it can be concluded that there were no crystallinity changes in the 
drug or interactions between the excipients and drug throughout the formulation proce-
dures.
However, reduced intensity of the endothermic peak of the drug in the PM and liqui-
solid formulation could be linked to the polymer dilution effect and/or solubilization of the 
drug in the melted polymer. These findings were fully consistent with XRD patterns. 
In vitro drug solubility and release studies
In vitro dissolution tests were carried out to analyze the release behavior of KCZ from 
the DC and liquisolid formulations (Fig. 3). The liquisolid compressed samples showed 
faster release patterns compared to the DC samples at the same pH. It was found that liqu-
isolid formulations (F3, F2 and F1) released at least 40‒53 % of the drug within 30 min, 
while DC samples had a drug release rate of about 17 % during this period. In addition, 
nearly 47‒60 % of the drug was released from liquisolid formulations in 90 min, while 
about 21 % was released from DC tablets within the same period of time (Fig. 3). The mo-
lecular dispersion of the drug in PEG 400 was one of the main parameters that were most 
likely to affect the release rate of the drug from liquisolid formulations. In other words, the 
molecularly dispersed drug can dissolve immediately after its disintegration in dissolu-
tion media and enhance the dissolution rate. The other reason for the enhanced release rate 
of liquisolid formulations compressed with DC samples could be attributed to their in-
creased surface area, i.e., as mentioned previously, the increased dissolution rate could be 
strongly connected to the fact that KCZ already exists in liquid medications (PEG 400 solu-
tion) while powder particles of the liquisolid formulation (cellulose and silica) are carrying 
it; consequently, its accelerated release was mainly due to surface availability and wettabil-
ity enhancement in the dissolution environment (14‒16, 30).
Fig. 3. Release profiles of ketoconazole in different formulations measured in simulated gastric fluid 
(mean ± SD, n = 3).
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Another reason that could explain the enhanced release rate of liquisolid compacts 
was their formulation and incorporation of PVP as an additive. PVP might inhibit the 
drug crystal growth (i.e., its precipitation from the supersaturated solution) (14) and in-
crease the drug exposed surface area in the dissolution environment due to its adsorption 
on the carrier. Furthermore, a larger amount of the molecularly dissolved drug (in PEG 
400) could be absorbed on the silica surface (because of its large surface area) (14‒16), in-
creasing the exposed drugs in the dissolution medium. Consequently, it would enhance 
the dissolution rate of liquisolid formulations. Furthermore, the graphs presented in Fig. 
3 imply that an increase in drug concentration or a decrease in PEG 400 concentration in 
liquisolid formulations would result in a decrease in the dissolution rate of liquisolid 
compacts. This might be explained by changes in the solubility or the molecularly dis-
persed form of the drug in liquisolid systems. Moreover, it can be concluded from the 
DSC and XRD data that the dissolution rate enhancement of KCZ liquisolid tablets was 
not due to the formation of complexes between KCZ and excipients or alterations in KCZ 
crystallinity.
Stability evaluation of liquisolid systems
Stability evaluations were conducted on optimized formulations to reveal the effect 
of aging on the hardness and dissolution behavior of KCZ liquisolid compressed tablets. 
The results of dissolution rate and hardness measurements showed no significant varia-
tions between the hardness of aged (8.5 ± 1.1 SC) and fresh (8.9 ± 1 SC) liquisolid compacts 
(p > 0.05). Therefore, the aging process did not affect the hardness of liquisolid compressed 
tablets. Dissolution graphs of the aged and fresh liquisolid compacts showed a lower re-
lease rate for aged liquisolid tablets compared to the fresh ones (Fig. 4). However, consider-
ing the similarity factor of the two dissolution profiles, it can be concluded that acceptable 
similarity exists between the two profiles, indicating that the dissolution behavior of KCZ 
optimized formulations was not affected by the aging process. As a result, one can sup-
pose that liquisolid tablets of KCZ will preserve their initial hardness and enhanced re-
lease behavior after 6 months.
Fig. 4. Effect of aging on dissolution profiles of ketoconazole liquisolid tablets (mean ± SD, n = 3).
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CONCLUSIONS
By adding PVP to a liquid medication, it is possible to load a higher amount of drug 
into liquisolid tablets. This is valuable for the preparation of liquisolid tablets using high 
dose drugs. Liquisolid tablets prepared using PVP as an additive into the liquid medica-
tion resulted in better dissolution profiles compared to DC compacts and other formula-
tions Furthermore, no crystalline structure transformation or interaction was detected 
during the procedure. Finally, aging had no influence on the hardness and release profile 
of liquisolid compacts.
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